Androgen deprivation therapy for prostate cancer: friend or foe to the cardiovascular system?

World J Urol. 2016 Jun;34(6):879-81. doi: 10.1007/s00345-015-1700-7. Epub 2015 Sep 30.

Authors

Kaiping Zhang¹, Li Zhang¹, Zongyao Hao¹, Chaozhao Liang²

Affiliations

¹ Department of Urology, The First Affiliated Hospital of Anhui Medical University, and Institute of Urology, Anhui Medical University, No. 218 Jixi Road, Hefei, 230022, Anhui Province, People's Republic of China.
² Department of Urology, The First Affiliated Hospital of Anhui Medical University, and Institute of Urology, Anhui Medical University, No. 218 Jixi Road, Hefei, 230022, Anhui Province, People's Republic of China. [email protected].

PMID: 26424563
DOI: 10.1007/s00345-015-1700-7

No abstract available

Publication types

Letter

MeSH terms

Androgen Antagonists / adverse effects*
Cardiovascular Diseases / etiology*
Gonadotropin-Releasing Hormone / agonists*
Humans
Male
Orchiectomy / adverse effects*
Prostatic Neoplasms / therapy*

Substances

Androgen Antagonists
Gonadotropin-Releasing Hormone